Caution advised in the use of CFTR modulator treatment for individuals harboring specific CFTR variants.
暂无分享,去创建一个
M. Corey | J. Rommens | M. Lewis | C. Castellani | C. Penland | K. Raraigh | J. Collaco | A. Stephenson | G. Cutting
[1] D. Taruscio,et al. Elexacaftor/tezacaftor/ivacaftor for CFTR variants giving rise to diagnostic uncertainty: Personalised medicine or over-medicalisation? , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[2] B. Quon,et al. Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review , 2020, Journal of clinical medicine.
[3] P. Negulescu,et al. G970R‐CFTR Mutation (c.2908G>C) Results Predominantly in a Splicing Defect , 2020, Clinical and translational science.
[4] G. Lam,et al. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis , 2020, Annals of the American Thoracic Society.
[5] D. Caimmi,et al. Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis. , 2020, American journal of respiratory and critical care medicine.
[6] A. Munck,et al. Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2years of treatment with ivacaftor in a real-world setting. , 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[7] T. Noah,et al. Worsening anxiety and depression after initiation of lumacaftor/ivacaftor combination therapy in adolescent females with cystic fibrosis. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[8] S. Leroy,et al. Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[9] C. Dryden,et al. The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review , 2016, Archives of Disease in Childhood.
[10] P. Hiatt,et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[11] George P Patrinos,et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene , 2013, Nature Genetics.
[12] F. van Goor,et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[13] J. Lehmann-Che,et al. A neutral variant involved in a complex CFTR allele contributes to a severe cystic fibrosis phenotype , 2005, Human Genetics.
[14] Y. Eto,et al. A Japanese patient homozygous for the H1085R mutation in the CFTR gene presents with a severe form of cystic fibrosis , 1999, Clinical genetics.
[15] Joseph F. Cotten,et al. Effect of Cystic Fibrosis-associated Mutations in the Fourth Intracellular Loop of Cystic Fibrosis Transmembrane Conductance Regulator* , 1996, The Journal of Biological Chemistry.